Randomized clinical trials (RCTs) with "hard" end points and meta-analyses of these trials should influence clinical practice because they represent the highest level of evidence. Health care behaviors based on less robust evidence are often established before such RCTs are conducted. If the results of high-quality RCTs contradict established practice, numerous barriers exist to their acceptance and implementation.
cently, their health effects have been studied in several RCTs and meta-analyses, many of which were reported in highimpact journals. Here, we report the relationship between these publications in influential journals and the use of ω-3 FAs. , and news reports generated within 2 weeks of each publication. We independently assessed editorial disposition toward the use of ω-3 FAs using a scale from 1 (clearly unfavorable) to 5 (clearly favorable).
Results | Between January 1, 2005, and December 31, 2012, a total of 18 RCTs (primary end points: 10 cardiovascular, 4 neurocognitive, 1 cancer, 1 immune, 1 gastrointestinal, and 1 respiratory) and 6 meta-analyses of RCTs (all cardiovascular primary end points) of ω-3 FAs were published in the highimpact journals 3-26 (Table) . Only 2 publications reported benefit of the intervention on the primary end point. 3,7 The median (range) editorial score was 4 (1.5-5), indicating overall enthusiasm for the use of ω-3 FAs (Table) . The median (range) number of news reports per publication was 11 (0-27). Between 2007 and 2012, sales of fish oils and ω-3 FA supplements in the United States increased steadily, from $425 to $1043 million ( Figure) . The median (range) year-on-year increase was $124 (104-150) million. Similar patterns of sales were observed in the United Kingdom and Australasia (data not shown).
Discussion | This analysis suggests that publications in prominent medical journals of RCTs and meta-analyses of RCTs of ω-3 FAs have had little effect on the use of these supplements. Sales of ω-3 FAs steadily increased despite contemporaneous accrual of high-level evidence that the supplements lack efficacy across a range of health outcomes for which their use is advocated. Since 10% of adults in the United States take an ω-3 FA or fish oil supplement, most commonly for heart health or to lower cholesterol, 27 the null results of 9 of the 10
RCTs and 5 of the 6 meta-analyses studying cardiovascular disease might have been expected to influence use. It remains to be seen whether a recently published trial sequential analysis, which reports proof of no efficacy of ω-3 FAs in the secondary prevention of cardiovascular disease, alters use of the supplements. 28 For prescribed interventions, numerous factors, including academic and/or medical specialists' biases, contribute to resistance to the translation into clinical practice of robust evidence that contradicts established behaviors. 29 The editorialists' positive views on ω-3 FAs may have influenced the responses of health practitioners to the results of the source trials. However, only 10% of those who take ω-3 FAs do so on the advice of a health care professional. 27 Additional factors that may contribute to increasing use of a nonprescribed intervention despite accumulating evidence of its ineffectiveness include anecdotal evidence, low cost, ready availability, assumptions of safety, supportive news reports, and selective presentation of evidence by the supplements industry. b Number of news stories generated within 2 weeks of publication.
c No hierarchy of end points was described.
d No statistically significant results in unadjusted analyses, but the authors reported a nonstandard adjusted analysis as the main finding. e Specified as secondary end points.
